Cargando…

Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial

BACKGROUND: Chronic hepatitis C (CHC) Patients, infected with genotype (GT) 2 or 3 are treated with Peg-IFN and ribavirin (RBV) (800 mg/day) for 24 weeks. Treatment duration can be shortened to 12-16 weeks if a higher dose of RBV (1.000/1.200 mg/day) was used without considerable loss of responsiven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maieron, Andreas, Metz-Gercek, Sigrid, Scherzer, Thomas-Matthias, Laferl, Hermann, Fischer, Gabriele, Bischof, Martin, Gschwantler, Michael, Ferenci, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141520/ https://www.ncbi.nlm.nih.gov/pubmed/21714878 http://dx.doi.org/10.1186/1756-0500-4-220

Ejemplares similares

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Ten years of antibiotic consumption in ambulatory care: Trends in prescribing practice and antibiotic resistance in Austria
por: Metz-Gercek, Sigrid, et al.
Publicado: (2009)

On Shortening the Duration of Labour
por: Gray, J.
Publicado: (1858)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

Case Report: Severe Interstitial Pneumonitis Secondary to Pegylated Interferon α-2b and Ribavirin Treatment of Hepatitis C Infection
por: Fuhrmann, Valentin, et al.
Publicado: (2004)

Methicillin-Resistant Staphylococcus aureus ST398 from Human Patients, Upper Austria
por: Krziwanek, Karina, et al.
Publicado: (2009)

Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
por: Chung, Woo Jin
Publicado: (2012)

Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial
por: Ferenci, Peter, et al.
Publicado: (2016)

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
por: Waldenström, Jesper, et al.
Publicado: (2016)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
por: Seo, Hee Yeon, et al.
Publicado: (2020)

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
por: Pellicelli, Adriano, et al.
Publicado: (2020)

Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis
por: Jachs, Mathias, et al.
Publicado: (2021)

High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo
por: Hu, Yanmin, et al.
Publicado: (2015)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C
por: Abenavoli, Ludovico, et al.
Publicado: (2011)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
por: You, Byung Chul, et al.
Publicado: (2012)

Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?
por: Dutta, Noton K., et al.
Publicado: (2015)

Shortened duration and reduced area of frozen soil in the Northern Hemisphere
por: Li, Ting, et al.
Publicado: (2021)

Ribavirin
Publicado: (2016)

Ribavirin
por: Hall, Caroline Breese
Publicado: (1985)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
por: Asselah, Tarik, et al.
Publicado: (2016)

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
por: Forns, Xavier, et al.
Publicado: (2015)

Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
por: Smirne, Carlo, et al.
Publicado: (2021)

Observations on the Duration and Course of Fever in Britain, and on the Efficacy of Medicine in Interrupting Its Course, and in Shortening Its Duration
por: Brown, William
Publicado: (1802)

Zinc Lozenges May Shorten the Duration of Colds: A Systematic Review
por: Hemilä, Harri
Publicado: (2011)

Is It Possible to Shorten the Duration of Adjuvant Chemotherapy for Locally Advanced Rectal Cancer?
por: You, Kai-Yun, et al.
Publicado: (2016)

Enriched Environment Shortens the Duration of Action Potentials in Cerebellar Granule Cells
por: Eshra, Abdelmoneim, et al.
Publicado: (2019)

Does feticide shorten termination duration in second trimester pregnancy terminations?
por: Şık, Aytek, et al.
Publicado: (2019)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
por: Kim, Haein, et al.
Publicado: (2022)

Outcomes after placement of a SX‐ELLA oesophageal stent for refractory variceal bleeding—A national multicentre study
por: Pfisterer, Nikolaus, et al.
Publicado: (2018)

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
por: Gane, Edward J., et al.
Publicado: (2017)

Shortening duration of ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections: A retrospective study
por: Fink, Doug L., et al.
Publicado: (2019)

Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
por: Tamai, Hideyuki, et al.
Publicado: (2016)

Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan
por: Igarashi, Ataru, et al.
Publicado: (2019)

Increased Duration of Dual Pegylated Interferon and Ribavirin Therapy for Genotype 1 Hepatitis C Post-liver Transplantation Increases Sustained Virologic Response: A Retrospective Review
por: Wells, Malcolm M., et al.
Publicado: (2013)

Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis
por: Drusano, George L., et al.
Publicado: (2014)

The Treatment of Surgical Inflammations by a New Method, Which Greatly Shortens Their Duration
Publicado: (1871)

Pyogenic Arthritis of the Fingers and the Wrist: Can We Shorten Antimicrobial Treatment Duration?
por: Meier, Rahel, et al.
Publicado: (2017)

Shortening of Overall Orthodontic Treatment Duration with Low-Intensity Pulsed Ultrasound (LIPUS)
por: Kaur, Harmanpreet, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pjl8s0p6dpf4isa883cfjh07up